Recognizing and managing akathisia.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D017109:Akathisia, Drug-Induced; D014151:Anti-Anxiety Agents / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000009:adverse effects*; D001569:Benzodiazepines; D002908:Chronic Disease; D003937:Diagnosis, Differential; D004409:Dyskinesia, Drug-Induced / Q000188:drug therapy; D006801:Humans; D009248:Nadolol; D011412:Propanolamines / Q000627:therapeutic use; D011433:Propranolol / Q000627:therapeutic use; D012559:Schizophrenia / Q000188:drug therapy
D000319:Adrenergic beta-Antagonists; D014151:Anti-Anxiety Agents; D014150:Antipsychotic Agents; D011412:Propanolamines; D001569:Benzodiazepines; D009248:Nadolol; D011433:Propranolol